2-cyclohexyl-2-(4-methoxyphenyl)-4-methyl-1H-imidazole-5(2H)-thione | 1260215-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 2-cyclohexyl-2-(4-methoxyphenyl)-4-methyl-1H-imidazole-5(2H)-thione
• 英文别名: 2-cyclohexyl-2-(4-methoxyphenyl)-4-methyl-1H-imidazole-5-thione
• CAS: 1260215-20-0
• 化学式: C₁₇H₂₂N₂OS
• 分子量: 302.44
• InChiKey: YMOBYQJTXXRYGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  65.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE LA NEURODÉGÉNÉRESCENCE ASSOCIÉE À DES MALADIES, TELLES QUE LA MALADIE D'ALZHEIMER OU LA DÉMENCE
  申请人：ASTRAZENECA AB

  公开号：WO2011002408A1

  公开（公告）日：2011-01-06

  The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式(I)的新化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理学，如唐氏综合征、β-淀粉样血管病，如但不限于脑淀粉样血管病或遗传性脑出血，与认知功能障碍相关的疾病，如但不限于MCI（“轻度认知功能障碍”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状，与疾病相关的神经退行性变化，如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆症、早发性痴呆症、老年性痴呆症以及与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆症。